SeeThruEquity Upgrades RXMD Price Target to $0.35 per Share

March 9, 2018
webadmin

MIAMI, March 9, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB: RXMD), a healthcare services and technology company, announces upgraded price target to $0.35 per share from SeeThruEquity.SeeThruEquity, a premier small and microcap research firm, released an updated analyst report today upgrading Progressive Care’s price target to $0.35 per share. The upgrade is based on recent news of the Company’s intent to acquire a pharmacy in Palm Beach County as well as increased sales, new product and technology development projects, and the acceptance Bitcoin. SeeThruEquity’s report issues analysis on the Company’s current business and releases new sales targets which provide the basis for the upgraded price target for RXMD.“We are excited to see that SeeThruEquity has initiated updated coverage of the Company,” stated S. Parikh Mars, CEO. "We believe that we are executing on our objectives as we take the Progressive Care to the next level. We are humbled by the response to our story and remain focused on delivering results to our patients and shareholders alike.”[pdf-embedder url="https://progressivecareus.com/wp-content/uploads/2018/03/RXMD-UPDATE-MAR-9-2018-FINAL.pdf" title="RXMD UPDATE MAR 9 2018" height="500" mobilewidth="200" scrolltotop="on"]Original Document Link: https://finance.yahoo.com/news/seethruequity-issues-progressive-care-inc-131500911.htmlGet connected and stay in touch with us on social media:Progressive Care Inc.https://www.facebook.com/ProgressiveCareUS/https://twitter.com/ProgressCareUSPharmCo, LLChttps://www.facebook.com/pharmcorx/https://twitter.com/PharmCoRxAbout Progressive CareProgressive Care Inc. (OTCQB:RXMD), through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long term care facilities, administration and practice management, utilization management, quality assurance, EHR Implementation, billing and coding, and health practice risk management.Cautionary Statement Regarding Forward Looking StatementsStatements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.ContactArmen KarapetyanSenior Advisor Business Developmentarmen@progressivecareus.comwww.progressivecareus.comwww.pharmcopharmacy.com